Profile: Valeant Pharmaceuticals International Inc (VRX.N)
Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.
The developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of dermatology and podiatry, neurology, gastrointestinal disorders, eye health, oncology and urology, dentistry, aesthetics, and women's health, and pharmaceutical products, OTC products and medical device products sold in Western Europe, Canada, Japan, Australia and New Zealand.
The Company's pharmaceutical products include Xifaxan, including tablets indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults and for the reduction in risk of overt hepatic encephalopathy recurrence in adults, and tablets indicated for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients of approximately 10 years of age and older; Wellbutrin XL, an extended-release formulation of bupropion indicated for the treatment of depressive disorder in adults; An Acne franchise, which includes Solodyn, a prescription oral antibiotic approved to treat only the red, pus-filled pimples of moderate to severe acne in patients of approximately 10 years of age and older, as well as Ziana, Clindagel, Acanya, Atralin, Retin-A franchise and Onexton Gel; Glumetza (metformin hydrochloride) extended release tablets, which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Provenge (sipuleucel-T), an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer, and Jublia (efinaconazole with over 10% topical solution), a topical azole indicated for the treatment of onychomycosis of the toenails (toenail fungus).
The Company offers Nitropress (sodium nitroprusside), which is indicated for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel (Isoproterenol hydrochloride) injections, which are indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy, for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation), for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available and for bronchospasm occurring during anesthesia; Xenazine, which is indicated for the treatment of chorea associated with Huntington's disease; Uceris (budesonide) extended release tablets, a prescription corticosteroid medicine used to help get mild to moderate ulcerative colitis under control (induce remission); Lotemax Gel, a topical corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery, and Arestin (minocycline hydrochloride), a subgingival sustained-release antibiotic.
The Company's OTC products are PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe formulations, which incorporate ceramides, cholesterol and fatty acids, which are essential for skin barrier repair and are used as adjunct therapy in the management of various skin conditions; Biotrue, a multi-purpose solution used to maintain potential of Hydrogen (pH) to match healthy tears and to prevent certain tear proteins from denaturing and fights germs for healthy contact lens wear, and Boston solution, a specialty cleansing solution design for gas permeable (GP) contact lenses.
The Company's portfolio of ophthalmic surgical products includes intraocular lenses, such as Akreos, enVista, Crystalens, and Trulign; a suite of surgical instruments, including Storz and Synergetics, and surgical equipment for cataract, refractive and vitreoretinal surgery, such as Stellaris PC, a vitreoretinal and cataract surgery system, VersaVIT2.0 for vitreoretinal surgery and the VICTUS femtosecond laser for cataract surgery; SofLens Daily Disposable Contact Lenses, which use ComfortMoist Technology and High Definition Optics, an aspheric design that reduces aspheric aberration over the range of powers; Biotrue ONEday; PureVision, a silicone hydrogel frequent replacement contact lens, and Thermage CPT system, which provides non-invasive treatment options using radiofrequency energy for skin tightening.
The Company's Generic Products are Tobramycin and Dexamethasone ophthalmic suspension, indicated for steroid responsive inflammatory ocular conditions, where superficial bacterial ocular infection or a risk of bacterial ocular infection exists; Metronidazole, which is indicated to treat bacterial infections of the vagina, stomach, skin, joints, and respiratory tract; Retin-A Micro (tretinoin gel) microsphere, an oil-free prescription-strength acne treatment, and Latanoprost, which is indicated to treat a type of glaucoma called open angle glaucoma and also ocular hypertension.
The Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products and medical device products. The Company's products are sold in Central and Eastern Europe (primarily Poland and Russia), Asia, Latin America (Mexico, Brazil, Argentina and Colombia, and exports out of Mexico to other Latin American markets), Africa and the Middle East. The branded generics and branded pharmaceuticals businesses in Europe, Asia, Latin America, Africa and the Middle East cover a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, diabetic therapies, and eye health products.
The Company's OTC products include ReNu Multiplus, a sterile, preserved solution used to lubricate and rewet soft (hydrophilic) contact lenses; Bedoyecta products, which act as energy improvement agents for fatigue related to age or chronic diseases, and as nervous system maintenance agents to treat neurotic pain and neuropathy; Artelac, a solution in the form of eye drops to treat dry eyes caused by chronic tear dysfunction, and Ocuvite, a lutein eye vitamin and mineral supplement that contains lutein (an antioxidant carotenoid), a nutrient that supports macular health by helping filter harmful blue light.
Valeant Pharmaceuticals International Inc
Laval, 2150 Saint-Elzear Blvd W
LAVAL QC H7L 4A8
Company Web Links
- BRIEF-FDA to inspect Nicox partner Bausch + Lomb
- BRIEF-Valeant says no safety concerns, additional clinical trials for approval of Latanoprostene Bunod
- BRIEF-Valeant and Progenics announce FDA approvals for relistor
- BRIEF-Valeant to host conference call on Aug. 9 to discuss Q2 results
- UPDATE 2-Hedge fund manager Ackman still betting against Herbalife